GlassScriptPhysician profile
Saurabh Gupta
NPI 1457669228
$1,204.42
in general payments reported to CMS, 2019-2025
18 companies · $622 in 2025
The $622 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $29.51 · 2021: $22.38 · 2023: $183 · 2024: $61.25 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $864 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.58 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $208.15 | 2019-2025 | Exalt Model D, X-Tack Endoscopic Helix Tacking System |
| 3-D Matrix, INC. | $187.50 | 2025 | |
| Steris Corporation | $125.30 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $115.33 | 2019 | |
| Janssen Biotech, INC. | $104.34 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $96.07 | 2025 | Entyvio |
| Fujifilm Healthcare Americas Corporation | $75.00 | 2023 | |
| Endogastric Solutions, INC | $53.50 | 2019 | |
| Qol Medical, LLC | $45.05 | 2024-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.50 | 2025 | Xifaxan |
| Abbvie INC. | $36.57 | 2019-2023 | |
| Intercept Pharmaceuticals, INC. | $28.36 | 2023 | Ocaliva |
| Akebia Therapeutics INC | $22.38 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.33 | 2020 | |
| Olympus America INC. | $16.49 | 2024 | Single Use Aspiration Needle Na-U200h |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $14.29 | 2019 | |
| Getinge USA Sales, LLC | $12.18 | 2020 | |
| Travere Therapeutics, INC. | $3.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saurabh Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.